162,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 1-2 Wochen
  • Gebundenes Buch

As the diabetes epidemic continues to burden the healthcare system, and with the literature supporting enhanced patient outcomes with improved glycemic control, the need for expertise in the clinical management of inpatient diabetes is an increasingly important and timely matter. While some books have been published on inpatient diabetes, this guide serves as a comprehensive but clinically relevant review of the available literature and recommended management for the key areas surrounding hospital diabetes management.
This book is designed to provide practical guidance on diabetes
…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
As the diabetes epidemic continues to burden the healthcare system, and with the literature supporting enhanced patient outcomes with improved glycemic control, the need for expertise in the clinical management of inpatient diabetes is an increasingly important and timely matter. While some books have been published on inpatient diabetes, this guide serves as a comprehensive but clinically relevant review of the available literature and recommended management for the key areas surrounding hospital diabetes management.

This book is designed to provide practical guidance on diabetes management for hospitalized patients. The number of topics covered is meant to be comprehensive and include discussion on many potential scenarios encountered on the inpatient service, but in a concise and user-friendly manner. This book is intended to be a valuable resource for fellows, residents, students, and existing providers looking to improve their knowledge and skills in evidence-based inpatient diabetes management. The enclosed chapters were written by many globally renowned physicians, researchers, and clinicians. Diabetes Management in Hospitalized Patients: A Comprehensive Clinical Guide is a valuable resource for endocrinologists, hospitalists, pharmacists, PAs and NPs, and all staff responsible for clinical care of these patients.


Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Rifka Schulman-Rosenbaum, MD, FACE, FACP is the Director of Inpatient Diabetes at Long Island Jewish (LIJ) Medical Center, Northwell Health in New Hyde Park, NY, and Professor of Medicine at the Zucker School of Medicine at Hofstra/Northwell. Dr. Schulman-Rosenbaum received her medical degree from the SUNY Downstate College of Medicine, summa cum laude. She trained in internal medicine residency and chief resident at the Long Island Jewish Medical Center, and with fellowship training in Endocrinology and Metabolism at the Icahn School of Medicine at Mount Sinai. Dr. Schulman-Rosenbaum specializes in management of inpatient diabetes and inpatient endocrinology. For more than a decade she has run a busy inpatient endocrine service full time, including supervision of a multidisciplinary diabetes team as well as endocrine fellows and other trainees. Under her leadership LIJ Medical Center has maintained certification with the Joint Commission for Advanced Inpatient Diabetes since 2014. Dr. Schulman-Rosenbaum participates in or leads numerous hospital committees and workgroups. Her research focuses on areas relating to inpatient diabetes, including hyperglycemia due to COVID-19 and Diabetes screening in the emergency department. She was the recipient of The Salzman Award for Excellence in Quality for Northwell Health in 2019 and has been awarded Northwell Health Teacher of the Year for 2023. Dr. Schulman-Rosenbaum is currently serving as the Chair of the Diabetes Disease State Network for the American Association of Clinical Endocrinology (AACE) and is the Vice Chair for the 2024 AACE annual meeting. She is the editor of a book in progress entitled "Diabetes Management in Hospitalized Patients: A Comprehensive Clinical Guide." Dr. Schulman-Rosenbaum is also the Adult sub-group leader on an international work group sponsored by JDRF to formalize guidelines on monitoring of antibody positive, pre-stage 3 type 1 diabetes.